![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
Vol. 14, Issue 10, 3977-3988, October 2003
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
–Signaling System
* Program in Cell Biology, Department of Pediatrics, National Jewish Medical and Research Center, Denver, Colorado 80206;
Department of Pharmacology, University of Colorado Health Sciences Center, Denver, Colorado 80262
Submitted January 10, 2003;
Revised May 30, 2003;
Accepted May 31, 2003
Monitoring Editor: Carl Henrik-Heldin
Secreted protein, acidic and rich in cysteine (SPARC) is a multifunctional secreted protein that regulates cell–cell and cell–matrix interactions, leading to alterations in cell adhesion, motility, and proliferation. Although SPARC is expressed in epithelial cells, its ability to regulate epithelial cell growth remains largely unknown. We show herein that SPARC strongly inhibited DNA synthesis in transforming growth factor (TGF)-
–sensitive Mv1Lu cells, whereas moderately inhibiting that in TGF-–insensitive Mv1Lu cells (i.e., R1B cells). Overexpression of dominant-negative Smad3 in Mv1Lu cells, which abrogated growth arrest by TGF-, also attenuated growth arrest stimulated by SPARC. Moreover, the extracellular calcium-binding domain of SPARC (i.e., SPARC-EC) was sufficient to inhibit Mv1Lu cell proliferation but not that of R1B cells. Similar to TGF- and thrombospondin-1, treatment of Mv1Lu cells with SPARC or SPARC-EC stimulated Smad2 phosphorylation and Smad2/3 nuclear translocation: the latter response to all agonists was abrogated in R1B cells or by pretreatment of Mv1Lu cells with neutralizing TGF- antibodies. SPARC also stimulated Smad2 phosphorylation in MB114 endothelial cells but had no effect on bone morphogenetic protein-regulated Smad1 phosphorylation in either Mv1Lu or MB114 cells. Finally, SPARC and SPARC-EC stimulated TGF-–responsive reporter gene expression through a TGF- receptor- and Smad2/3-dependent pathway in Mv1Lu cells. Collectively, our findings identify a novel mechanism whereby SPARC inhibits epithelial cell proliferation by selectively commandeering the TGF- signaling system, doing so through coupling of SPARC-EC to a TGF- receptor- and Smad2/3-dependent pathway.
Corresponding author. E-mail address: schiemannwp{at}njc.org.
This article has been cited by other articles:
|
|
 |
|
  T. M. Allington, A. J. Galliher-Beckley, and W. P. Schiemann Activated Abl kinase inhibits oncogenic transforming growth factor-{beta} signaling and tumorigenesis in mammary tumors FASEB J, December 1, 2009; 23(12): 4231 - 4243. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. W.M. Schellings, D. Vanhoutte, M. Swinnen, J. P. Cleutjens, J. Debets, R. E.W. van Leeuwen, J. d'Hooge, F. Van de Werf, P. Carmeliet, Y. M. Pinto, et al. Absence of SPARC results in increased cardiac rupture and dysfunction after acute myocardial infarction J. Exp. Med., January 16, 2009; 206(1): 113 - 123. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Neil, K. M. Johnson, R. A. Nemenoff, and W. P. Schiemann Cox-2 inactivates Smad signaling and enhances EMT stimulated by TGF-{beta} through a PGE2-dependent mechanisms Carcinogenesis, November 1, 2008; 29(11): 2227 - 2235. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Rotta, G. Matteoli, E. Mazzini, P. Nuciforo, M. P. Colombo, and M. Rescigno Contrasting roles of SPARC-related granuloma in bacterial containment and in the induction of anti-Salmonella typhimurium immunity J. Exp. Med., March 17, 2008; 205(3): 657 - 667. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Neil and W. P. Schiemann Altered TAB1:I{kappa}B Kinase Interaction Promotes Transforming Growth Factor {beta}-Mediated Nuclear Factor-{kappa}B Activation during Breast Cancer Progression Cancer Res., March 1, 2008; 68(5): 1462 - 1470. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. J Sansom, F. C Mansergh, M. J Evans, J. A Wilkins, and A. R Clarke Deficiency of SPARC suppresses intestinal tumorigenesis in APCMin/+ mice Gut, October 1, 2007; 56(10): 1410 - 1414. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Au, M. W. Richter, A. J. Vincent, W. Tetzlaff, R. Aebersold, E. H. Sage, and A. J. Roskams SPARC from Olfactory Ensheathing Cells Stimulates Schwann Cells to Promote Neurite Outgrowth and Enhances Spinal Cord Repair J. Neurosci., July 4, 2007; 27(27): 7208 - 7221. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. B. Kessler and A. M. Delany Increased Notch 1 Expression and Attenuated Stimulatory G Protein Coupling to Adenylyl Cyclase in Osteonectin-Null Osteoblasts Endocrinology, April 1, 2007; 148(4): 1666 - 1674. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Robert, C. Gaggioli, O. Bailet, C. Chavey, P. Abbe, E. Aberdam, E. Sabatie, A. Cano, A. Garcia de Herreros, R. Ballotti, et al. SPARC Represses E-Cadherin and Induces Mesenchymal Transition during Melanoma Development. Cancer Res., August 1, 2006; 66(15): 7516 - 7523. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. Green, G. M. Manikhas, S. Orlov, B. Afanasyev, A. M. Makhson, P. Bhar, and M. J. Hawkins Abraxane(R), a novel Cremophor(R)-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer Ann. Onc., August 1, 2006; 17(8): 1263 - 1268. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Said and K. Motamed Absence of Host-Secreted Protein Acidic and Rich in Cysteine (SPARC) Augments Peritoneal Ovarian Carcinomatosis Am. J. Pathol., December 1, 2005; 167(6): 1739 - 1752. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. J. Gradishar, S. Tjulandin, N. Davidson, H. Shaw, N. Desai, P. Bhar, M. Hawkins, and J. O'Shaughnessy Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil-Based Paclitaxel in Women With Breast Cancer J. Clin. Oncol., November 1, 2005; 23(31): 7794 - 7803. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. E. Gruber, E. H. Sage, H. J. Norton, S. Funk, J. Ingram, and E. N. Hanley Jr. Targeted Deletion of the SPARC Gene Accelerates Disc Degeneration in the Aging Mouse J. Histochem. Cytochem., September 1, 2005; 53(9): 1131 - 1138. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. V. Durvasula and S. J. Shankland Mechanical strain increases SPARC levels in podocytes: implications for glomerulosclerosis Am J Physiol Renal Physiol, September 1, 2005; 289(3): F577 - F584. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S G Cole, M E Begbie, G M F Wallace, and C L Shovlin A new locus for hereditary haemorrhagic telangiectasia (HHT3) maps to chromosome 5 J. Med. Genet., July 1, 2005; 42(7): 577 - 582. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Alvarez, F. Prada, E. Salvatierra, A. I. Bravo, V. P. Lutzky, C. Carbone, F. J. Pitossi, H. E. Chuluyan, and O. L. Podhajcer Secreted Protein Acidic and Rich in Cysteine Produced by Human Melanoma Cells Modulates Polymorphonuclear Leukocyte Recruitment and Antitumor Cytotoxic Capacity Cancer Res., June 15, 2005; 65(12): 5123 - 5132. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. R. Albig and W. P. Schiemann Identification and Characterization of Regulator of G Protein Signaling 4 (RGS4) as a Novel Inhibitor of Tubulogenesis: RGS4 Inhibits Mitogen-activated Protein Kinases and Vascular Endothelial Growth Factor Signaling Mol. Biol. Cell, February 1, 2005; 16(2): 609 - 625. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. L. Lagan, P. Pantelidis, E. A. Renzoni, C. Fonseca, P. Beirne, A. B. Taegtmeyer, C. P. Denton, C. M. Black, A. U. Wells, R. M. du Bois, et al. Single-nucleotide polymorphisms in the SPARC gene are not associated with susceptibility to scleroderma Rheumatology, February 1, 2005; 44(2): 197 - 201. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q. Shi, S. Bao, J. A. Maxwell, E. D. Reese, H. S. Friedman, D. D. Bigner, X.-F. Wang, and J. N. Rich Secreted Protein Acidic, Rich in Cysteine (SPARC), Mediates Cellular Survival of Gliomas through AKT Activation J. Biol. Chem., December 10, 2004; 279(50): 52200 - 52209. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. Sokol and W. P. Schiemann Cystatin C Antagonizes Transforming Growth Factor {beta} Signaling in Normal and Cancer Cells Mol. Cancer Res., March 1, 2004; 2(3): 183 - 195. [Abstract] [Full Text] [PDF]
|
|
